FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Peptide Therapy Market Set for Major Expansion with New Telehealth Programs
Voltar à Biblioteca de Pesquisa

Peptide Therapy Market Set for Major Expansion with New Telehealth Programs

November 20, 2026
Share
Pesquisa Emergente

Baseado em pesquisa emergente. Esses achados são promissores, mas requerem validação adicional.

Sobre esta Análise

Este artigo é uma síntese assistida por inteligência artificial de um item noticiário ou lista de ensaios clínicos recentemente publicado. É intenção fornecer uma visão rápida e acessível para a comunidade de pesquisa em peptídeos. Para obter a precisão completa, sempre consulte o

Peptide Therapy Market Set for Major Expansion with New Telehealth Programs

This week saw a significant development in the peptide therapy market as two major telehealth companies launched new programs. The Health and Human Services (HHS) department recently eased regulations on compounding pharmacies, allowing them to offer more drugs like BPC-157, which has sparked excitement among researchers and clinicians alike.

Background

Peptide therapies have been gaining traction in recent years due to their unique properties and potential benefits for various health conditions. These small chains of amino acids can mimic or enhance the body's natural processes, making them a promising area of research. However, regulatory hurdles often slow down the availability of these treatments. The recent changes by HHS are expected to streamline access to peptide therapies through compounding pharmacies, which play a crucial role in providing customized medications that aren't commercially available.

The telehealth industry has been at the forefront of leveraging technology to improve patient care and accessibility. With this new regulatory landscape, companies like Hims and Noom have seen an opportunity to expand their service offerings into peptide therapy programs. This move is likely to attract a wider range of patients seeking innovative treatment options for conditions such as chronic pain, gastrointestinal disorders, and wound healing.

Key Details

The launch of these telehealth programs marks a pivotal moment in the peptide therapy market. Both Hims and Noom have integrated comprehensive platforms that connect patients with healthcare providers who specialize in peptide treatments. These platforms offer consultations, personalized treatment plans, and access to compounded peptides through partner pharmacies. The ease of use and convenience factor are expected to draw more consumers into exploring peptide therapies.

Regulatory changes by the Health and Human Services department play a critical role in this expansion. By making it easier for compounding pharmacies to provide these treatments, HHS has effectively reduced barriers that previously limited patient access. This move also underscores the growing recognition of peptides as viable therapeutic options within the medical community.

Key Takeaways

  • Increased Accessibility: Patients can now more easily obtain peptide therapies through telehealth platforms and partner pharmacies.
  • Regulatory Ease: Recent changes by HHS have simplified the process for compounding pharmacies to offer drugs like BPC-157.
  • Telehealth Expansion: Companies such as Hims and Noom are expanding their service offerings to include peptide therapy programs.
  • Growing Market Potential: The combination of regulatory ease and telehealth integration is expected to drive significant growth in the peptide market.

What This Means

For the peptide community, these developments signal a period of rapid expansion and increased accessibility. Researchers and clinicians will have more opportunities to explore and implement peptide therapies for various conditions. Patients seeking innovative treatment options can now benefit from streamlined access through telehealth platforms. As the market continues to grow, it is crucial that regulatory bodies maintain oversight to ensure patient safety and efficacy standards are met.

---

Source: STAT News — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

Nota do Editor

Esta análise foi gerada usando ferramentas de inteligência artificial e revisada pela equipe editorial da Peptide Contacts. Embora busquemos a precisão, o conteúdo gerado por inteligência artificial pode conter erros ou omissões. Encorajamos os leitores a revisar o fonte original para detalhes completos, metodologia e dados.

A Peptide Contacts fornece resumos de pesquisa curados para fins informativos apenas. Este conteúdo não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.

Comments

Sign in to join the discussion

Este artigo foi gerado usando inteligência artificial e pode conter inaccuracy. É fornecido para fins informativos apenas e não constitui conselhos médicos. Sempre verifique as informações com a fonte original e consulte um provedor de saúde qualificado antes de tomar qualquer decisão relacionada à saúde.